Product Description
Serlopitant, an oral, once-daily neurokinin 1 receptor antagonist, for treatment of psoriatic pruritus in a phase 2, randomized clinical trial (NCT03343639).
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vyne Therapeutics
Company Location: BRIDGEWATER NJ 08807
Company CEO: David Domzalski
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Neurodermatitis|Prurigo|Pruritus|Psoriasis|Dermatitis, Atopic
Phase 2: Prurigo|Neurodermatitis|Pruritus|Alcoholism|Dermatitis, Atopic|Burns Unspecified|Refractory Chronic Cough|Urinary Incontinence|Unexplained Chronic Cough|Psoriasis|Overactive Bladder|Epidermolysis Bullosa
Phase 1: Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT03836001 | P2 |
Completed |
Epidermolysis Bullosa|Pruritus |
2021-12-06 |
|
| Itch | P3 |
Terminated |
Prurigo|Dermatitis, Atopic|Psoriasis|Pruritus |
2020-04-08 |
|
| 2017-004210-25 | P3 |
Completed |
Prurigo|Pruritus |
2020-02-06 |
|
| MTI-105 | P3 |
Completed |
Prurigo|Neurodermatitis|Pruritus |
2020-01-14 |